Power Ultrasound and the Production of Mesoscopic Particles and Aqueous Dispersions - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Power Ultrasound and the Production of Mesoscopic Particles and Aqueous Dispersions
The authors discuss advanced sonocrystallization particle-engineering techniques for manufacturing mesoscopic particles.

Pharmaceutical Technology


With an ever-increasing demand for mesoscopic particles of pharmaceutical materials, whether microcrystalline or nanocrystalline colloidal in form, with defined physical and chemical characteristics, the benefits offered by ultrasound-assisted particle-engineering technologies are valuable. Because ultrasound-assisted technologies are single-stage, solution-to-particle processes and have the potential to meet the scale-up requirements, attractive solutions are available to address many of the problems in engineering pharmaceutical materials and particle design.

Ultrasound should have a bright future in industrial processing, crystallization, and particle engineering. True industrial adaptation of the techniques discussed will necessitate the design and building of new ultrasonication equipment for laboratory use and production in a safe, effective, and economic manner.

Many processing opportunities can be approached with flow-cell technology. Power ultrasound equipment should find its way into many manufacturing facilities. New techniques such as SAX and DISCUS could become the default methods for producing perfect mesoscopic particles.

Graham Ruecroft* is chief technical officer, and Dipesh Parikh is a senior scientist at Prosonix, The Magdelen Centre, Robert Robinson Ave., Oxford Science Park, Oxford OX4 4GA, UK, tel. +44 1865 784244,

*To whom all correspondence should be addressed.


1. B. Aungst, "Intestinal Permeation Enhancers," J. Pharm. Sci. 89 (4), 429–442 (2000).

2. A.H.L. Chow et al., "Particle Engineering for Pulmonary Drug Delivery," Pharm. Res. 24 (3), 411–437 (2007)

3. B.E. Rabinow, "Nanosuspensions in Drug Delivery," Nat. Rev. Drug Discov. 3 (9), 785 (2004).

4. C. Leuner, J. Dressman, "Improving Drug Solubility for Oral Delivery Using Solid Dispersions," Eur. J. Pharm. Biopharm. 50 (1), 47–60 (2000).

5. Y. Wu, F. Kesisoglou, S. Panmai, "Nanosizing—Oral Formulation Development and Biopharmaceutical Evaluation," Adv. Drug Deliv. Rev. 59 (7), 631–644 (2007).

6. Synthetic Organic Sonochemistry, J.L. Luche, Ed. (Plenum Press, New York, 1998).

7. G. Ruecroft et al., "Sonocrystallization: The Use of Ultrasound for Improved Industrial Crystallization," Org. Process Res. Dev. 9 (6), 923–932 (2005).

8. G. Ruecroft, "Sound Science in Molecules and Particles," Speciality Chemicals Magazine (June), 60 (2008).

9. Prosonix. Entrainment in Anti-Solvent. Br. Patent Application 07.05159.2, 2007.

10. Prosonix, Crystalline Particles Using Immiscible Anti-Solvent: Solvent, Br. Patent Application 07.11680.9, 2007.

11. Glaxo Group Limited, Novel Process, Patent WO/2003/035035, 2003.

12. AstraZeneca, Process for the Preparation of Crystalline Nano-Particle Dispersions, Patent WO/2004/009057, 2004.

13. Syngenta Limited, Process for Preparing a Crystal Suspension, US Patent 6,517,853, 2003.

14. Z. Guo et al., "Effect of Ultrasound on Anti-Solvent Crystallization Process," J. Cryst. Growth 273 (3–4), 555–563 (2004).

15. C. Virone et al., "Primary Nucleation Induced by Ultrasonic Cavitation," J. Cryst. Growth 294 (1), 9–15 (2006).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here